A S Boehle1, B Sipos, U Kliche, H Kalthoff, P Dohrmann. 1. Department for General Surgery and Thoracic Surgery, Christian-Albrechts-University, Kiel, Germany. boehle@surgery.uni-kiel.de
Abstract
BACKGROUND: Combretastatin A-4 prodrug (CA-4PD) has been identified as a potent antivascular agent in various rodent tumor models. The aim of this study was to investigate the effect of CA-4PD on human non-small cell lung cancer (NSCLC). METHODS: Cytostatic and cytotoxic effects of CA-4PD on selected NSCLC cells, Colo-699 and KNS-62, were studied in vitro. After subcutaneous xenotransplantation the effect of systemically administrated CA-4PD on tumor growth was investigated in vivo. A newly established orthotopic xenotransplant model was employed to estimate prolongation of survival after intrapulmonary tumor induction with secondary metastatic disease. RESULTS: In vitro, CA-4PD displayed a time and dose dependent antiproliferative effect on human lung cancer cells. In vivo, CA-4PD significantly delayed growth of subcutaneously induced lung cancer. This growth delay was translated into a prolongation of survival in the metastasizing orthotopic xenotransplant model. CONCLUSIONS: In vitro CA-4PD inhibits proliferation of NSCLC cells, most likely by disruption of microtubule assembly. In vivo, systemic treatment inhibits growth of subcutaneously xenotransplanted tumors by an antivascular effect. In the case of metastasizing human lung cancer this translated into a prolongation of survival.
BACKGROUND:Combretastatin A-4 prodrug (CA-4PD) has been identified as a potent antivascular agent in various rodent tumor models. The aim of this study was to investigate the effect of CA-4PD on humannon-small cell lung cancer (NSCLC). METHODS: Cytostatic and cytotoxic effects of CA-4PD on selected NSCLC cells, Colo-699 and KNS-62, were studied in vitro. After subcutaneous xenotransplantation the effect of systemically administrated CA-4PD on tumor growth was investigated in vivo. A newly established orthotopic xenotransplant model was employed to estimate prolongation of survival after intrapulmonary tumor induction with secondary metastatic disease. RESULTS: In vitro, CA-4PD displayed a time and dose dependent antiproliferative effect on humanlung cancer cells. In vivo, CA-4PD significantly delayed growth of subcutaneously induced lung cancer. This growth delay was translated into a prolongation of survival in the metastasizing orthotopic xenotransplant model. CONCLUSIONS: In vitro CA-4PD inhibits proliferation of NSCLC cells, most likely by disruption of microtubule assembly. In vivo, systemic treatment inhibits growth of subcutaneously xenotransplanted tumors by an antivascular effect. In the case of metastasizing humanlung cancer this translated into a prolongation of survival.
Authors: Matthew T Macdonough; Tracy E Strecker; Ernest Hamel; John J Hall; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney Journal: Bioorg Med Chem Date: 2013-07-23 Impact factor: 3.641
Authors: George R Pettit; Collin R Anderson; Eric J Gapud; M Katherine Jung; John C Knight; Ernest Hamel; Robin K Pettit Journal: J Nat Prod Date: 2005-08 Impact factor: 4.050
Authors: Jeremy Griggs; Jeremy N Skepper; Gerry A Smith; Kevin M Brindle; James C Metcalfe; Robin Hesketh Journal: Am J Pathol Date: 2002-03 Impact factor: 4.307
Authors: Christine A Herdman; Laxman Devkota; Chen-Ming Lin; Haichan Niu; Tracy E Strecker; Ramona Lopez; Li Liu; Clinton S George; Rajendra P Tanpure; Ernest Hamel; David J Chaplin; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney Journal: Bioorg Med Chem Date: 2015-12-15 Impact factor: 3.641
Authors: M F McCarty; A Takeda; O Stoeltzing; W Liu; F Fan; N Reinmuth; M Akagi; C Bucana; P F Mansfield; A Ryan; L M Ellis Journal: Br J Cancer Date: 2004-02-09 Impact factor: 7.640
Authors: L J Williams; D Mukherjee; M Fisher; C C Reyes-Aldasoro; S Akerman; C Kanthou; G M Tozer Journal: Br J Pharmacol Date: 2014-11 Impact factor: 8.739